Perrigo Completes Acquisition of GSK OTC Brands

Perrigo Company plc has completed its previously announced acquisition of the over-the-counter (OTC) brands from GlaxoSmithKline (GSK) in an all cash transaction valued at EUR 200 million ($224 million). GSK sold these products as part of its commitments to the European Commission and other regulators to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis International AG.

As previously reported, Perrigo acquired the following assets: (1) GSK’s NiQuitin nicotine-replacement therapy (NRT) business, primarily in the European Economic Area (EEA) and Brazil, and Novartis’s legacy Australian NRT business, including the Nicotinell brand; (2) several assorted OTC brands, including Coldrex (cold and flu treatment) across the EEA, and Panodil (pain relief), Nezeril (nasal decongestant), and Nasin (nasal decongestant) in Sweden; and Novartis’s legacy cold-sore management products, primarily in the EEA, marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips and Vectatone.

Source: Perrigo

Leave a Reply

Your email address will not be published. Required fields are marked *